NEXT-GENERATION
PROTEOMICS CRO SERVICE
We measure, identify and quantify proteomes to find biomarkers that our partners can develop into diagnostic tests and novel drugs to improve health.
Deep proteome coverage. DIA-MS is highly multiplexed and compatible with virtually any biological sample containing proteins. It is capable of confidently and reproducibly identifying up to 11,000 proteins, the most of any proteomic technique.
(Spin off from Max Planck Institute in Golm)
Impact of Therapeutic Oligos on Biotech growth in 2022
Therapeutic Oligos have a new impact in the drug development market after mRNA Covid booster for Biotech companies. More than 200 companies globally were investigating RNA-based therapeutic technologies, financed by governmental or venture capital.